Hyman Charles D Has $145,000 Stake in Opko Health, Inc. (OPK)

Hyman Charles D continued to hold its position in shares of Opko Health, Inc. (NASDAQ:OPK) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,119 shares of the biotechnology company’s stock at the end of the first quarter. Hyman Charles D’s holdings in Opko Health were worth $145,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the company. Piedmont Investment Advisors LLC acquired a new position in shares of Opko Health during the third quarter worth about $622,000. Whalerock Point Partners LLC acquired a new position in shares of Opko Health during the third quarter worth about $2,100,000. Russell Investments Group Ltd. acquired a new position in shares of Opko Health during the fourth quarter worth about $648,000. National Planning Corp boosted its position in shares of Opko Health by 1.2% in the fourth quarter. National Planning Corp now owns 16,240 shares of the biotechnology company’s stock worth $138,000 after buying an additional 200 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI boosted its position in shares of Opko Health by 35.4% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 34,339 shares of the biotechnology company’s stock worth $319,000 after buying an additional 8,981 shares during the last quarter. Institutional investors own 23.66% of the company’s stock.

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Opko Health, Inc. (NASDAQ:OPK) traded up 1.24% during midday trading on Friday, reaching $6.53. 3,929,136 shares of the company were exchanged. Opko Health, Inc. has a 52-week low of $5.99 and a 52-week high of $12.15. The stock’s market capitalization is $3.65 billion. The firm’s 50-day moving average price is $6.76 and its 200 day moving average price is $8.36.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.02. The company had revenue of $296.10 million during the quarter, compared to analysts’ expectations of $313.36 million. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. Opko Health’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period last year, the company earned ($0.02) earnings per share. Equities analysts predict that Opko Health, Inc. will post ($0.20) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/06/16/opko-health-inc-opk-stake-maintained-by-hyman-charles-d-updated-updated.html.

OPK has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Saturday, February 18th. Jefferies Group LLC lowered their price target on shares of Opko Health from $10.00 to $8.00 and set a “hold” rating for the company in a report on Thursday, March 2nd. Standpoint Research reiterated a “buy” rating and set a $14.00 price target on shares of Opko Health in a report on Sunday, March 5th. Guggenheim started coverage on shares of Opko Health in a report on Tuesday, March 14th. They set a “buy” rating and a $25.00 price target for the company. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $19.50 price target on shares of Opko Health in a report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $15.64.

In other Opko Health news, Vice Chairman Jane Ph D. Hsiao acquired 40,000 shares of Opko Health stock in a transaction dated Wednesday, May 10th. The stock was bought at an average cost of $6.97 per share, with a total value of $278,800.00. Following the completion of the transaction, the insider now owns 24,723,133 shares of the company’s stock, valued at $172,320,237.01. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Phillip Md Et Al Frost acquired 9,200 shares of Opko Health stock in a transaction dated Wednesday, March 29th. The stock was acquired at an average cost of $8.14 per share, with a total value of $74,888.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $24,981,261.14. The disclosure for this purchase can be found here. Insiders purchased 2,698,000 shares of company stock worth $18,464,543 in the last 90 days. 40.74% of the stock is currently owned by corporate insiders.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply